Amyloidosis TTR Flow Reserve Evaluation (AMYTRE)
Amyloidosis TTR Flow Reserve Evaluation (AMYTRE)
ClinicalTrials.gov ID: NCT05103943
Sponsor: Centre Hospitalier Régional d'Orléans
Information provided by: Centre Hospitalier Régional d'Orléans (Responsible Party)
Last Update Posted: 2023-07-20
Brief Summary:
Anginal symptoms and signs of ischemia have been reported in some patients with cardiac amyloidosis (TTR) without obstructive epicardial coronary artery disease (CAD).
It was found that coronary microvascular dysfunction was highly prevalent in subjects with cardiac amyloidosis, even in the absence of epicardial CAD. The investigators found lower stress and rest myocardial blood flow (MBF) and lower myocardial flow reserve (MFR) in their cardiac PET (Positron emission tomography) study (13N), including 21 patients.
The advances in SPECT technology including cadmium zinc telluride (CZT) detectors allow to evaluate the MBF and MFR estimation by SPECT as shown in both experimental animal models and also in clinical studies with comparison to PET.
SPECT is more widely available than cardiac PET. Thus, the investigators would like:
1. to confirm the results of Dorbala et al using SPECT, and
2. to go further with evaluation of the effect of Tafamidis on microvascular dysfunction.
Official Title:
Amyloidosis TTR Flow Reserve Evaluation
Intervention / Treatment:
- Other: SPECT MPI
| Category | Value |
|---|---|
| Study Start (Actual) | 2022-02-24 |
| Primary Completion (Estimated) |
2026-02
|
| Study Completion (Estimated) | 2026-02 |
| Enrollment (Estimated) | 50 |
| Study Type | Interventional |
| Phase | Not Applicable |
| Other Study ID Numbers |
CHRO-2021-05 |